FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2007678892> ?p ?o ?g. }

• W2007678892 endingPage "453" @default.
• W2007678892 startingPage "449" @default.
• W2007678892 abstract "No AccessJournal of UrologyClinical Urology: Original Articles1 Feb 1998INFLUENCE OF FINASTERIDE ON FREE AND TOTAL SERUM PROSTATE SPECIFIC ANTIGEN LEVELS IN MEN WITH BENIGN PROSTATIC HYPERPLASIA Jurgen Pannek, Leonard S. Marks, Jay D. Pearson, Harry G. Rittenhouse, Daniel W. Chan, Erlinda D. Shery, Glenn J. Gormley, Eric N.P. Subong, Cindy A. Kelley, Elizabeth Stoner, and Alan W. Partin Jurgen PannekJurgen Pannek More articles by this author , Leonard S. MarksLeonard S. Marks More articles by this author , Jay D. PearsonJay D. Pearson More articles by this author , Harry G. RittenhouseHarry G. Rittenhouse More articles by this author , Daniel W. ChanDaniel W. Chan More articles by this author , Erlinda D. SheryErlinda D. Shery More articles by this author , Glenn J. GormleyGlenn J. Gormley More articles by this author , Eric N.P. SubongEric N.P. Subong More articles by this author , Cindy A. KelleyCindy A. Kelley More articles by this author , Elizabeth StonerElizabeth Stoner More articles by this author , and Alan W. PartinAlan W. Partin More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(01)63946-6AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Finasteride therapy for benign prostatic hyperplasia (BPH) results in a marked lowering of serum prostate specific antigen (PSA) levels. However, little is known about the effect of finasteride on unbound or free serum levels of PSA. Such information would be important since percent free PSA may substantially improve the cancer specificity of PSA testing. Thus, we prospectively studied the effect of finasteride therapy on total and free serum PSA levels. Materials and Methods: In a randomized, placebo controlled, double-blind trial 40 men with histologically confirmed BPH (age range 52 to 78 years) were treated with either 5 mg. finasteride daily (26 patients) for 9 months or placebo (14) for 6 months. Prostate volume was assessed by transrectal ultrasound. Serum levels of free and total PSA were measured from archived serum samples stored at −70C at baseline and for as long as 9 months of treatment. Results: In the finasteride group mean total PSA levels declined from 3.0 ng./ml. at baseline to 1.5 ng./ml. after 6 months of treatment (50% decrease, p < 0.01). In the placebo group, with similar baseline levels, no significant change was observed. PSA density declined significantly in finasteride treated men (p <0.01) but not in men receiving placebo. The mean percent free PSA (13 to 17% at baseline) was not altered significantly by finasteride or placebo. Conclusions: Total PSA serum levels decreased by an average of 50% during finasteride therapy but percent free PSA did not change significantly. This information is potentially useful in the interpretation of PSA data used for early detection of prostate cancer in men receiving finasteride. However, further studies are required to demonstrate the use of percent free PSA to detect the development of cancer. References 1 : The effect of finasteride on prostate-specific antigen in men with benign prostatic hyperplasia.. Prostate.1993; 22: 31. Google Scholar 2 : The effect of finasteride on prostate specific antigen: review of available data.. J. Urol.1996; 155: 3. Link, Google Scholar 3 : Effect of finasteride on prostate-specific antigen density.. Urology.1994; 43: 53. Google Scholar 4 : Multicenter, randomized, double-blind, plazebo-controlled study to investigate the effect of finasteride (MK-906) on stage D prostate cancer.. J. Urol.1992; 148: 1201. Link, Google Scholar 5 : Effect of long term treatment with finasteride on free and total PSA in serum.. J. Urol.1996; 156: 698A. part 2, abstract 1547. Google Scholar 6 : Prostate specific antigen: its role in early detection, staging and monitoring of prostatic carcinoma.. J. Endourol.1989; 3: 227. Google Scholar 7 : Prostate specific antigen in the staging of localized prostate cancer: Influence of tumor differentiation, tumor volume and benign hyperplasia.. J. Urol.1990; 143: 747. Link, Google Scholar 8 : Evaluation of percentage of free serum PSA to improve specificity of prostate cancer screening.. J.A.M.A.1995; 274: 1214. Google Scholar 9 : The use of prostate-specific antigen and free/total prostate-specific antigen in the diagnosis of localized prostate cancer.. Urol. Clin. N. Amer.1996; 23: 531. Google Scholar 10 : The effect of finasteride in men with benign prostatic hyperplasia. The finasteride study group.. New Engl. J. Med.1992; 327: 1185. Google Scholar 11 : Finasteride (MK-906) in the treatment of benign prostatic hyperplasia.. Prostate.1993; 22: 291. Google Scholar 12 : Prostate tissue composition and response to finasteride in men with symptomatic benign prostatic hyperplasia.. J. Urol.1997; 157: 2171. Link, Google Scholar 13 : The American Urological Association symptom index for benign prostatic hyperplasia.. J. Urol.1992; 145: 1549. Google Scholar 14 : Newton-Raphson and EM algorithms for linear mixed-effects models for repeated-measures data.. J. Amer. Stat. Assn.1988; 83: 1014. Google Scholar 15 : Effect of finasteride on serum PSA concentration in men with benign prostatic hyperplasia.. Urol. Clin. N. Amer.1993; 20: 627. Google Scholar 16 : Physiologic (intraindividual) variation of serum prostate-specific antigen in 814 men from a screening population. Urology.1996; 47: 343. Google Scholar 17 : Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new era.. Urology.1995; 45: 729. Google Scholar 18 : Enzymatic activity of prostate specific antigen and its reactions with extracellular serine proteinase inhibitors.. Eur. J. Biochem.1990; 194: 755. Google Scholar 19 : Significance of different molecular forms of serum PSA: the free, non-complexed form of PSA versus that complexed to alpha sub 1-antichymotrypsin.. Urol. Clin. N. Amer.1993; 20: 681. Google Scholar 20 : A complex between prostate-specific antigen and alpha sub 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer. Assay of the complex improves clinical sensitivity for cancer.. Cancer Res.1991; 51: 222. Google Scholar 21 : Serum prostate-specific antigen complexed to alpha sub 1-antichymotrypsin as an indicator of prostate cancer.. J. Urol.1993; 150: 100. Abstract, Google Scholar 22 : Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios.. J. Urol.1995; 154: 1090. Link, Google Scholar 23 : Analysis of percent free PSA for prostate cancer detection: Influence of total PSA, prostate volume, and age.. Urology.1996; 48: 55. Google Scholar 24 : Treatment of benign prostatic hyperplasia with 5 alpha-reductase inhibitor: morphological changes in patients who fail to respond.. J. Clin. Path.1996; 49: 324. Google Scholar 25 : Comparison of percent free PSA levels in men with BPH treated with finasteride and terazosin.. J. Urol.1996; 155: 571A. part 2, abstract 1040. Google Scholar 26 : Effect of finasteride on free and total serum prostate-specific antigen in men with benign prostatic hyperplasia.. Brit. J. Urol.1996; 78: 405. Google Scholar 27 : Stability of free prostate-specific antigen in serum samples under a variety of sample collection and sample storage conditions.. Urology.1996; 48: 33. Google Scholar 28 : In vitro stability of free prostate specific antigen (PSA) complexed to alpha 1-antichymotrypsin in blood samples.. Urology.1996; 48: 81. Google Scholar 29 : Biologic variability of prostate-specific antigen and its usefulness as a marker for prostate cancer: effects of finasteride.. Urology.1997; 50: 13. Google Scholar James Buchanan Brady Urological Institute and the Department of Clinical Chemistry, Johns Hopkins Medical Institution, Baltimore, Maryland, Hybritech, Inc., San Diego, California, Merck Research Laboratories, Rahway, New Jersey, and Urological Sciences Research Foundation, Culver City, California.© 1998 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byKaplan S (2018) Re: Resveratrol Reduces the Levels of Circulating Androgen Precursors but has No Effect on Testosterone, Dihydrotestosterone, PSA Levels or Prostate Volume. A 4-Month Randomised Trial in Middle-Aged MenJournal of Urology, VOL. 195, NO. 6, (1838-1838), Online publication date: 1-Jun-2016. Volume 159Issue 2February 1998Page: 449-453 Advertisement Copyright & Permissions© 1998 by American Urological Association, Inc.MetricsAuthor Information Jurgen Pannek More articles by this author Leonard S. Marks More articles by this author Jay D. Pearson More articles by this author Harry G. Rittenhouse More articles by this author Daniel W. Chan More articles by this author Erlinda D. Shery More articles by this author Glenn J. Gormley More articles by this author Eric N.P. Subong More articles by this author Cindy A. Kelley More articles by this author Elizabeth Stoner More articles by this author Alan W. Partin More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W2007678892 created "2016-06-24" @default.
• W2007678892 creator A5003945364 @default.
• W2007678892 creator A5011689017 @default.
• W2007678892 creator A5014021064 @default.
• W2007678892 creator A5039913744 @default.
• W2007678892 creator A5040028162 @default.
• W2007678892 creator A5050395853 @default.
• W2007678892 creator A5058589611 @default.
• W2007678892 creator A5061357972 @default.
• W2007678892 creator A5063449536 @default.
• W2007678892 creator A5078373142 @default.
• W2007678892 creator A5078939311 @default.
• W2007678892 date "1998-02-01" @default.
• W2007678892 modified "2023-10-17" @default.
• W2007678892 title "INFLUENCE OF FINASTERIDE ON FREE AND TOTAL SERUM PROSTATE SPECIFIC ANTIGEN LEVELS IN MEN WITH BENIGN PROSTATIC HYPERPLASIA" @default.
• W2007678892 cites W107210901 @default.
• W2007678892 cites W11097077 @default.
• W2007678892 cites W1847856759 @default.
• W2007678892 cites W1971063393 @default.
• W2007678892 cites W1971667801 @default.
• W2007678892 cites W1984103570 @default.
• W2007678892 cites W1984515024 @default.
• W2007678892 cites W2013120447 @default.
• W2007678892 cites W2015328657 @default.
• W2007678892 cites W2019490921 @default.
• W2007678892 cites W2019609101 @default.
• W2007678892 cites W2055063381 @default.
• W2007678892 cites W2067530870 @default.
• W2007678892 cites W2067535120 @default.
• W2007678892 cites W2073865693 @default.
• W2007678892 cites W2078573596 @default.
• W2007678892 cites W2081283602 @default.
• W2007678892 cites W2083030660 @default.
• W2007678892 cites W2088723575 @default.
• W2007678892 cites W2117018586 @default.
• W2007678892 cites W2408053455 @default.
• W2007678892 cites W2993539218 @default.
• W2007678892 cites W4234194238 @default.
• W2007678892 cites W4251469393 @default.
• W2007678892 cites W4294549545 @default.
• W2007678892 doi "https://doi.org/10.1016/s0022-5347(01)63946-6" @default.
• W2007678892 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9649261" @default.
• W2007678892 hasPublicationYear "1998" @default.
• W2007678892 type Work @default.
• W2007678892 sameAs 2007678892 @default.
• W2007678892 citedByCount "60" @default.
• W2007678892 countsByYear W20076788922012 @default.
• W2007678892 countsByYear W20076788922014 @default.
• W2007678892 countsByYear W20076788922015 @default.
• W2007678892 countsByYear W20076788922016 @default.
• W2007678892 countsByYear W20076788922017 @default.
• W2007678892 countsByYear W20076788922019 @default.
• W2007678892 countsByYear W20076788922020 @default.
• W2007678892 countsByYear W20076788922021 @default.
• W2007678892 countsByYear W20076788922022 @default.
• W2007678892 countsByYear W20076788922023 @default.
• W2007678892 crossrefType "journal-article" @default.
• W2007678892 hasAuthorship W2007678892A5003945364 @default.
• W2007678892 hasAuthorship W2007678892A5011689017 @default.
• W2007678892 hasAuthorship W2007678892A5014021064 @default.
• W2007678892 hasAuthorship W2007678892A5039913744 @default.
• W2007678892 hasAuthorship W2007678892A5040028162 @default.
• W2007678892 hasAuthorship W2007678892A5050395853 @default.
• W2007678892 hasAuthorship W2007678892A5058589611 @default.
• W2007678892 hasAuthorship W2007678892A5061357972 @default.
• W2007678892 hasAuthorship W2007678892A5063449536 @default.
• W2007678892 hasAuthorship W2007678892A5078373142 @default.
• W2007678892 hasAuthorship W2007678892A5078939311 @default.
• W2007678892 hasConcept C121608353 @default.
• W2007678892 hasConcept C126322002 @default.
• W2007678892 hasConcept C126894567 @default.
• W2007678892 hasConcept C147483822 @default.
• W2007678892 hasConcept C203014093 @default.
• W2007678892 hasConcept C2775874879 @default.
• W2007678892 hasConcept C2776235491 @default.
• W2007678892 hasConcept C2777562237 @default.
• W2007678892 hasConcept C2781406297 @default.
• W2007678892 hasConcept C29456083 @default.
• W2007678892 hasConcept C71924100 @default.
• W2007678892 hasConceptScore W2007678892C121608353 @default.
• W2007678892 hasConceptScore W2007678892C126322002 @default.
• W2007678892 hasConceptScore W2007678892C126894567 @default.
• W2007678892 hasConceptScore W2007678892C147483822 @default.
• W2007678892 hasConceptScore W2007678892C203014093 @default.
• W2007678892 hasConceptScore W2007678892C2775874879 @default.
• W2007678892 hasConceptScore W2007678892C2776235491 @default.
• W2007678892 hasConceptScore W2007678892C2777562237 @default.
• W2007678892 hasConceptScore W2007678892C2781406297 @default.
• W2007678892 hasConceptScore W2007678892C29456083 @default.
• W2007678892 hasConceptScore W2007678892C71924100 @default.
• W2007678892 hasIssue "2" @default.
• W2007678892 hasLocation W20076788921 @default.
• W2007678892 hasLocation W20076788922 @default.
• W2007678892 hasOpenAccess W2007678892 @default.
• W2007678892 hasPrimaryLocation W20076788921 @default.
• W2007678892 hasRelatedWork W1987346431 @default.
• W2007678892 hasRelatedWork W2014505656 @default.

• next